Xponential Fitness, Inc.

Xponential Fitness is a curator of leading boutique fitness brands across multiple verticals. Our mission is to make highly specialized workouts in motivating, community-based environments accessible to everyone. We are the largest boutique fitness franchisor in the United States with over 1,750 studios operating across nine distinct brands. Our diversified portfolio of brands spans a […]

July 17, 2021 Read More

Candel Therapeutics

We are a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Our engineered viruses are designed to induce immunogenic death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Our approach combines an in-depth knowledge of viral immunotherapy with extensive clinical experience […]

July 16, 2021 Read More

Ocean Biomedical

(Note: Ocean Biomedical withdrew its IPO plans in an SEC filing dated Feb. 16, 2023. The clinical biotech announced Feb. 15, 2023, that it had gone public by completing its initial business combination with a SPAC.) We are a biopharmaceutical company that seeks to bridge the “bench-to-bedside” gap between medical research discoveries and patient solutions. We do […]

Read More

Outbrain Inc.

Founded in 2006, Outbrain pioneered the online content recommendation category. Today our platform enables over 7,000 online properties, including many of the world’s most prestigious publications, helping them engage their users and monetize their visits. We have delivered over $3 billion in direct revenue to our media partners since inception. Some key media partners include Asahi […]

Read More

Elicio Therapeutics, Inc.

(Note: Elicio Therapeutics, Inc. withdrew its IPO plans in an SEC filing dated Sept. 13, 2022. The IPO was postponed in late July 2021. Elicio Therapeutics filed its S-1 in June 2021.)  We are a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. For therapies designed […]

Read More

Regencell Bioscience Holdings Ltd.

We are an early-stage bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”). (Incorporated in the Cayman Islands) Our goal is to improve the lives of ADHD and ASD patients, their […]

Read More

StoneBridge Acquisition Corp.

We will focus our search on a target with operations or prospective operations in the consumer technology, communications, software, SaaS, fintech or media sectors, which we refer to as the “new economy sectors”. In addition, we are focusing our search for target businesses in the following key verticals: Ecommerce, Fintech, SaaS (Software as a Service), […]

Read More

Bilander Acquisition Corp.

We intend to focus our search for a target business in the technology sector. (Bilander Acquisition is a new blank-check company or SPAC incorporated in Delaware.) True Wind Capital, a technology-focused private investment firm, is our advisory platform. Our chairman, Mr. James H. Greene, Jr., is a founding partner of True Wind Capital. We intend […]

July 15, 2021 Read More

Core & Main, Inc.

We are a leading specialized distributor of water, wastewater, storm drainage and fire protection products, and related services, to municipalities, private water companies and professional contractors across municipal, non-residential and residential end markets nationwide. Our specialty products and services are used in the maintenance, repair, replacement and construction of water and fire protection infrastructure. We are one […]

Read More

AbSci Corp.

Our mission is to change the world, one protein at a time. We founded AbSci with the goal of creating better medicines and helping them reach patients sooner. We recognized the extraordinary medical and economic potential of protein-based drugs (biologics), but also the significant challenges the biopharmaceutical industry faces to both discover novel biologics and […]

Read More
Page 164 of 301« First...102030...162163164165166...170180190...Last »